TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38489173

Group type: EXPERIMENTAL
Intervention: Cohort enrolled in Special Care Unit for BPSD (SCU-B)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Cohort not enrolled in Special Care Unit for BPSD (non-SCU-B)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Age increase
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Patient education level increase
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Neuropsychiatric Inventory total increase
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Total Mini-Mental State Examination
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Gender (females versus males)
Number of subjects: 508
Study: 38489186

Group type: EXPERIMENTAL
Intervention: ADAS-Cog 12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADCS-ADL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QoL-AD
Number of subjects: 0
Study: 38489236

Group type: EXPERIMENTAL
Intervention: Sema7A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sema7A-/- animals
Number of subjects: 0
Study: 38489346

Group type: EXPERIMENTAL
Intervention: Mothers-only
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Parents-combined
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control
Number of subjects: 390
Study: 38489493

Group type: EXPERIMENTAL
Intervention: Dynamic Choice Intervention (DCP)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard of Care (SEARCH)
Number of subjects: 400
Study: 38489552

Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Myosteatosis
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Visceral obesity
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Postoperative worsening sarcopenia
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Postoperative worsening myosteatosis
Number of subjects: 240
Study: 38489664

Group type: EXPERIMENTAL
Intervention: First-stage tissue expander (TE) insertion
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Second-stage TE exchange
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Risk factors for infection after first-stage procedure
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Risk factors for infection after second-stage procedure
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy
Number of subjects: 1058
Study: 38489667

Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: C allele
Number of subjects: 603
Study: 38489858

Group type: EXPERIMENTAL
Intervention: dB+TopoCyclo (n=24)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: dB+TOTEM/TEMIRI (n=15)
Number of subjects: 39
Study: 38490057

Group type: EXPERIMENTAL
Intervention: Topotecan (0.75 mg/m²) and Paclitaxel (TP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topotecan (0.75 mg/m²) and Cisplatin (TC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin-containing arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 0
Study: 38490102

Group type: EXPERIMENTAL
Intervention: PeriCord (engineered tissue graft consisting of a decellularised pericardial matrix and umbilical cord Wharton's jelly mesenchymal stromal cells)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PeriCord
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study: 38490230

Group type: EXPERIMENTAL
Intervention: Stepped collaborative care (once-weekly cognitive behavioural therapy for 50-60 min via telemedicine)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Stepped collaborative care
Number of subjects: 459

Group type: COMPARATOR
Intervention: Standard of care (screening and referral to a health-care provider for treatment of symptoms)
Number of subjects: 459
Study: 38490263

Group type: EXPERIMENTAL
Intervention: Tailored counseling and navigation (TCN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Targeted print (TP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study: 38490284

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (website + text messaging + additional features)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Original intervention (website only)
Number of subjects: 195
Study: 38490532

Group type: EXPERIMENTAL
Intervention: 50 g/d prune
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: 100 g/d prune
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control (no-prune)
Number of subjects: 183
Study: 38490651

Group type: EXPERIMENTAL
Intervention: Local muscle vibrations (LMVs) at 80 Hz for the interventional group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Local muscle vibrations (LMVs) at 40 Hz plus a foam band for the control group
Number of subjects: 100
Study: 38490660

Group type: EXPERIMENTAL
Intervention: LSALT peptide 5 mg intravenously daily for up to 14 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 38490668

Group type: EXPERIMENTAL
Intervention: Lupus Low Disease Activity State (LLDAS) attainment
Number of subjects: 680

Group type: COMPARATOR
Intervention: Non-LLDAS
Number of subjects: 680
Study: 38490697

Group type: EXPERIMENTAL
Intervention: MRI treat-to-target strategy
Number of subjects: 131

Group type: COMPARATOR
Intervention: Conventional treat-to-target strategy
Number of subjects: 131
Study: 38491111

Group type: EXPERIMENTAL
Intervention: Durable polymer drug-eluting stents (DP-DESs)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Biodegradable polymer drug-eluting stents (BP-DESs)
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Both groups (DP-DES and BP-DES)
Number of subjects: 620
Study: 38491141

Group type: EXPERIMENTAL
Intervention: Children with sickle cell disease
Number of subjects: 72

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 72
Study: 38491190

Group type: EXPERIMENTAL
Intervention: Circulating apoM
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 182

Group type: COMPARATOR
Intervention: Surgery-induced slimming program
Number of subjects: 182
Study: 38491260

Group type: EXPERIMENTAL
Intervention: Supervised HRVB
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Home-based HRVB
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 44
Study: 38491303

Group type: EXPERIMENTAL
Intervention: Wim Hof Method with cold exposure (WHM-C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wim Hof Method without cold exposure (WHM-NC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wim Hof Method (WHM-C and WHM-NC)
Number of subjects: 60
Study: 38491364

Group type: EXPERIMENTAL
Intervention: Clinical outcome assessments (COAs)
Number of subjects: 188
Study: 38491376

Group type: EXPERIMENTAL
Intervention: Evidence-based intervention (EBI; protocol-based hypertension treatment)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Team-based collaborative care (implementation strategy)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Adaptations planned amid COVID-19
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Quantitative programmatic data analysis (July 2019-July 2021)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Qualitative thematic analysis
Number of subjects: 18
Study: 38491429

Group type: EXPERIMENTAL
Intervention: hs-CRP < 1.0 mg/L
Number of subjects: 105

Group type: COMPARATOR
Intervention: hs-CRP ≥ 1.0 mg/L
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Borderline large artery elasticity
Number of subjects: 105

Group type: COMPARATOR
Intervention: Normal large artery elasticity
Number of subjects: 105

Group type: COMPARATOR
Intervention: OxLDL
Number of subjects: 105
Study: 38491460

Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38491507

Group type: EXPERIMENTAL
Intervention: Standard MAP (50-60 mmHg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High MAP (70-80 mmHg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-tailored MAP (comparable to the patient's preoperative MAP)
Number of subjects: 0
Study: 38491540

Group type: EXPERIMENTAL
Intervention: BBT-VR-HT
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MD-MR
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: BBT-VR-C
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: BBT-MR
Number of subjects: 42
Study: 38491546

Group type: EXPERIMENTAL
Intervention: slow-paced breathing condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: random-paced breathing condition
Number of subjects: 0
Study: 38491559

Group type: EXPERIMENTAL
Intervention: Guideline-based care (GBC)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: GBC plus nicotine metabolism-informed care (MIC)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: GBC plus counseling guided by a polygenic risk score (PRS) for lung cancer
Number of subjects: 92
Study: 38491795

Group type: EXPERIMENTAL
Intervention: Benralizumab 10/30 mg according to weight (<35/≥35 kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 30
Study: 38491965

Group type: COMPARATOR
Intervention: Bed-Cycle
Number of subjects: 186

Group type: COMPARATOR
Intervention: Book-Exe
Number of subjects: 186

Group type: COMPARATOR
Intervention: SoC
Number of subjects: 186

Group type: COMPARATOR
Intervention: Combined exercise (Bed-Cycle and Book-Exe)
Number of subjects: 186
Study: 38492010

Group type: EXPERIMENTAL
Intervention: Oral sulfate tablets (OST)
Number of subjects: 254

Group type: COMPARATOR
Intervention: 2 L-polyethylene glycol/ascorbate (2 L-PEG/Asc)
Number of subjects: 254
Study: 38492035

Group type: EXPERIMENTAL
Intervention: Bisphosphonate users
Number of subjects: 27405

Group type: COMPARATOR
Intervention: Nonusers
Number of subjects: 27405
Study: 38492078

Group type: EXPERIMENTAL
Intervention: Extreme hypofractionated radiotherapy (RT) with concomitant boost to the dominant intraprostatic lesion (DIL)
Number of subjects: 65
Study: 38492157

Group type: EXPERIMENTAL
Intervention: Tepotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab ± chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel ± nintedanib
Number of subjects: 0
Study: 38492506

Group type: EXPERIMENTAL
Intervention: Manually driven hysteroscopic tissue removal system
Number of subjects: 55

Group type: COMPARATOR
Intervention: Motor driven hysteroscopic tissue removal system
Number of subjects: 55
Study: 38492517

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the subthalamic nucleus (STN-DBS)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Medication therapy
Number of subjects: 170
Study: 38492558

Group type: EXPERIMENTAL
Intervention: Oblique stabilizers
Number of subjects: 30

Group type: COMPARATOR
Intervention: Perpendicular stabilizers
Number of subjects: 30
Study: 38492626

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 0
Study: 38492667

Group type: EXPERIMENTAL
Intervention: Positive SARS-CoV-2 nasopharyngeal RT-PCR
Number of subjects: 2410

Group type: COMPARATOR
Intervention: Negative serology or equivocal at delivery and no positive RT-PCR
Number of subjects: 2410
Study: 38492765

Group type: EXPERIMENTAL
Intervention: Nature-based exercise
Number of subjects: 104

Group type: COMPARATOR
Intervention: Indoor exercise
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Heart rate variability measures
Number of subjects: 104
Study: 38492903

Group type: EXPERIMENTAL
Intervention: UPA 45 mg once daily (UPA45)
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 1021
Study: 38492904

Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg (induction)
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg (maintenance)
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Placebo (induction and maintenance)
Number of subjects: 1021
Study: 38493021

Group type: EXPERIMENTAL
Intervention: Avutometinib
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Avutometinib/VS-4718
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3

Group type: COMPARATOR
Intervention: VS-4718
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Avutometinib, FAK inhibitor defactinib, and their combination
Number of subjects: 3
Study: 38493055

Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agents (n=281; 60%)
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Antibiotics (n=118; 25%)
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Cefazolin (52% of antibiotic-related reactions)
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 765
Study: 38493088

Group type: EXPERIMENTAL
Intervention: Emollient therapy (not specified dosage or duration)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Current neonatal skincare practices (petroleum jelly application, cooking oil, and other natural oils)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Cultural norms and experiences of new mothers
Number of subjects: 93
Study: 38493216

Group type: EXPERIMENTAL
Intervention: During the COVID-19 pandemic school closures, children with obesity experienced decreases in physical activity and sleep duration.
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Resumption of in-person activities after school closures.
Number of subjects: 94
Study: 38493287

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Short telomeres (TL < 20th percentile)
Number of subjects: 462
Study: 38493348

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38493482

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative haploidentical bone marrow transplant (BMT) with thiotepa and posttransplant cyclophosphamide (PTCy)
Number of subjects: 70
Study: 38493531

Group type: EXPERIMENTAL
Intervention: Women with cardiogenic shock
Number of subjects: 772

Group type: COMPARATOR
Intervention: Men with cardiogenic shock
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Both sexes
Number of subjects: 772
Study: 38493832

Group type: EXPERIMENTAL
Intervention: Aficamten 5-15 mg once daily for 10 weeks
Number of subjects: 41
Study: 38493909

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Moderate-Intensity Steady State (MISS)
Number of subjects: 382
Study: 38493953

Group type: EXPERIMENTAL
Intervention: Glutamine oral suspension
Number of subjects: 50

Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 50
Study: 38494157

Group type: EXPERIMENTAL
Intervention: Intermittent dosing regimens of cefoxitin
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Continuous infusion of cefoxitin
Number of subjects: 123
Study: 38494380

Group type: EXPERIMENTAL
Intervention: Androgen annihilation therapy (AAT; leuprolide, abiraterone acetate plus prednisone, and apalutamide) plus metastasis-directed stereotactic body radiotherapy (SBRT) for 6 months
Number of subjects: 28
Study: 38494412

Group type: EXPERIMENTAL
Intervention: MVA-BN-WEV vaccine (2 doses, 4 weeks apart)
Number of subjects: 45
Study: 38494493

Group type: EXPERIMENTAL
Intervention: Minimally Invasive Micro Sclerotomy (MIMS) procedure
Number of subjects: 120
Study: 38494525

Group type: EXPERIMENTAL
Intervention: Bacillus clausii spore probiotics (LiveSpo CLAUSY; 2 billion CFU/5 mL ampoule) at high dosages of 4-6 ampoules a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacillus clausii spore probiotics (LiveSpo CLAUSY)
Number of subjects: 0
Study: 38494526

Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE) after 3-month neo-adjuvant chemotherapy.
Number of subjects: 17
Study: 38494571

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg/day) with lifestyle education
Number of subjects: 240

Group type: COMPARATOR
Intervention: Lifestyle education alone
Number of subjects: 240
Study: 38494574

Group type: EXPERIMENTAL
Intervention: Tirzepatide (various doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study: 38494597

Group type: EXPERIMENTAL
Intervention: Durvalumab plus concurrent chemoradiotherapy (cCRT) with cisplatin
Number of subjects: 8
Study: 38494847

Group type: EXPERIMENTAL
Intervention: Lu AF82422 (75, 225, 750, 2250, 4500, and 9000 mg for cohorts A1-A6; 2250 and 9000 mg for cohorts B1 and B2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lu AF82422
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38495101

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38495115

Group type: EXPERIMENTAL
Intervention: Wearable UV dosimeter and UV counseling from a dermatologist
Number of subjects: 97

Group type: COMPARATOR
Intervention: UV counseling from a dermatologist
Number of subjects: 97
Study: 38495521

Group type: EXPERIMENTAL
Intervention: Blended mobile-based lifestyle intervention
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study: 38495608

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (AL) treatment (441mg, 662mg, or 882mg every 4 weeks or 882mg every 6 weeks) for six months
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (AL) treatment
Number of subjects: 51
Study: 38496180

Group type: EXPERIMENTAL
Intervention: Tenecteplase 0.25 mg/kg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 38496316

Group type: EXPERIMENTAL
Intervention: Meditation training for four weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38496326

Group type: EXPERIMENTAL
Intervention: Apple Watch
Number of subjects: 41
Study: 38496516

Group type: EXPERIMENTAL
Intervention: Uterine fibroids present
Number of subjects: 7030

Group type: EXPERIMENTAL
Intervention: Uterine fibroids diagnosed based on ICD code (n=297)
Number of subjects: 7030

Group type: EXPERIMENTAL
Intervention: Asymptomatic incidental ultrasound diagnosis of uterine fibroids (n=192)
Number of subjects: 7030

Group type: COMPARATOR
Intervention: Women without uterine fibroids
Number of subjects: 7030
Study: 38496619

Group type: EXPERIMENTAL
Intervention: Dasatinib plus quercetin (senolytic treatment)
Number of subjects: 0
Study: 38497150

Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 94
Study: 38497241

Group type: EXPERIMENTAL
Intervention: BI 690517 40 mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: BI 690517 (all doses)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: BI 690517 10 mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 58
Study: 38497347

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 23
Study: 38497454

Group type: EXPERIMENTAL
Intervention: Left ventricular dominance
Number of subjects: 766

Group type: COMPARATOR
Intervention: Right ventricular dominance
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 766

Group type: COMPARATOR
Intervention: RV dominance
Number of subjects: 766
Study: 38497706

Group type: EXPERIMENTAL
Intervention: Donor human milk
Number of subjects: 483

Group type: COMPARATOR
Intervention: Preterm infant formula
Number of subjects: 483
Study: 38497709

Group type: EXPERIMENTAL
Intervention: ZEN-3694 and ZEN-3791 quantification using LC-MS/MS method
Number of subjects: 0
Study: 38497740

Group type: EXPERIMENTAL
Intervention: Shorter duration between pretreatment assessment and Session 1
Number of subjects: 20
Study: 38497955

Group type: EXPERIMENTAL
Intervention: EHR-based patient portal reminders
Number of subjects: 262085

Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 262085

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 262085
Study: 38497987

Group type: EXPERIMENTAL
Intervention: Peer Coaching (PC)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Peer Coaching and Practice Facilitation (PCPF)
Number of subjects: 1209

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 1209
Study: 38497992

Group type: EXPERIMENTAL
Intervention: Video laryngoscopy
Number of subjects: 7736

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 7736
Study: 38498030

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)-based smoking cessation smartphone app, 4 weeks intervention
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group received a 'thank you' message
Number of subjects: 206
Study: 38498084

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) in combination with CHOP (G-CHOP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab (R) with CHOP (R-CHOP)
Number of subjects: 0
Study: 38498139

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg (subcutaneous)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo followed by Risankizumab
Number of subjects: 443
Study: 38498140

Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study: 38498142

Group type: EXPERIMENTAL
Intervention: 60 mg CM-chitosan (KioMedine)
Number of subjects: 49
Study: 38498141

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 964

Group type: COMPARATOR
Intervention: Placebo (inactive drug) followed by Risankizumab 150 mg
Number of subjects: 964
Study: 38498153

Group type: EXPERIMENTAL
Intervention: Cystocele patients with SUI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bladder neck mobility
Number of subjects: 0
Study: 38498397

Group type: EXPERIMENTAL
Intervention: Robot-assisted distal pancreatectomy (RDP)
Number of subjects: 1672

Group type: COMPARATOR
Intervention: Laparoscopic distal pancreatectomy (LDP)
Number of subjects: 1672